Amneal builds end-to-end biosimilars capacity in the U.S.
Amneal has expanded its U.S. biosimilars capabilities with the acquisition of Kashiv BioSciences.
Amneal
AAM comments on Amneal's U.S. expansion of end-to-end biosimilars development with their acquisition of Kashiv BioSciences
Adds Chicago research and development facility, New Jersey manufacturing site
Amneal announces full study population interim Phase 4 ELEVATE-PD results, reinforcing previously reported benefits of CREXONT in Parkinson's Disease
Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groups.
Amneal to acquire Kashiv BioSciences to create global biosimilar leader
Company's preliminary Q1 results reflect continued growth and raising 2026 Full Year Guidance.
Amneal announces BLA submission of biosimilar candidate to XOLAIR
Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal.
Amneal gets FDA approval of sodium oxybate oral solution
Sodium oxybate oral solution is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Amneal announces proposed refinancing of existing credit agreement
The proposed transactions are subject to market conditions and other factors, and there can be no assurance as to whether or when these transactions may be completed, or as to the actual size or terms of the transactions.